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ABSTRACT 
 
Ferrets are valuable animal models for the study of many human diseases. Cystic 
fibrosis (CF) and pancreatitis are two such human diseases that could benefit from a 
ferret model. The pancreatic disease processes that occur in the ferret animal model may 
allow researchers to investigate the pathophysiology of these diseases and help to 
develop new therapeutics for them. Trypsin-like immunoreactivity (TLI) is a non-
invasive diagnostic tool used to assess exocrine pancreatic function in humans, dogs, and 
cats. Therefore, the major objective of this project was to purify trypsin from ferret 
pancreas and to set up and analytically validate a radioimmunoassay (RIA) for the 
measurement of TLI in ferret serum.  
Ferrets euthanized for unrelated projects had their pancreata removed and frozen 
at -80°C for further purification. Ferret trypsin was purified from pancreatic tissue and 
antiserum against ferret trypsin was raised in rabbits. Tracer was produced by the 
chloramine-T method. A radioimmunoassay was set up and analytically validated by 
determination of dilutional parallelism, spiking recovery, intra-assay variability, inter-
assay variability, and sensitivity. A reference interval was established from 35 healthy 
ferret serum samples. A small group of ferrets with acute pancreatitis (AP; n = 3) and 
healthy controls (HC; n = 4) were analyzed by the new TLI RIA. 
We conclude that the ferret TLI RIA is analytically sensitive, accurate, precise, 
reproducible, and sufficiently linear for the measurement of TLI in serum samples from 
ferrets. All AP ferrets had higher serum TLI concentrations than HC ferrets, although the 
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sample size was small. Further studies evaluating the usefulness of measuring serum 
ferret TLI concentrations in animal models with AP and CF are underway. 
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NOMENCLATURE 
 
AP Acute pancreatitis 
CCK Cholecystokinin 
CF Cystic fibrosis 
CFTR Cystic fibrosis conductance regulator 
CPM Counts per minute 
EPI Exocrine pancreatic insufficiency 
IRT Immunoreactive trypsinogen test 
LLOD Lower limit of detection 
RIA Radioimmunoassay 
TLI Trypsin-like immunoreactivity 
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1. INTRODUCTION  
 
1.1 Radioimmunoassays for the measurement of trypsin-like immunoreactivity in 
serum 
 Human trypsin was first purified from pancreatic tissue by Travis and Roberts [1] 
in 1969, and the first radioimmunoassay (RIA) for the measurement of human trypsin-
like immunoreactivity (TLI) was developed by Geokas and Brodrick [2] in 1979. The 
TLI RIA measures not only trypsin, but also its zymogen trypsinogen. Trypsinogen is 
produced only in the acinar cells of the pancreas, so measurement of this inactive 
precursor provides a minimally-invasive tool for the assessment of exocrine pancreatic 
function. Also, serum concentrations of trypsin and trypsinogen and therefore TLI may 
increase when there is pancreatic inflammation [3].   
In humans, newborn screening for cystic fibrosis (CF) includes testing for TLI 
concentration in serum (or dried blood spots). Infants with high TLI concentrations are 
promptly retested in order to reconfirm CF as well as to continue to evaluate them for 
CF. Over time, pancreatic exocrine cell destruction leads to decreased secretion of 
pancreatic enzymes and serum TLI concentrations that are characteristic of pancreatic 
insufficiency. In turn, CF patients with pancreatic insufficiency require lifelong enzyme 
supplementation [4]. 
To date, there are three other species besides humans for which an immunoassay 
for the measurement of TLI in serum has been developed: dogs, cats, and horses [5,6,7]. 
Despite ferrets being a well-known animal model for human CF and a potential animal 
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model for human pancreatitis, to the author’s knowledge, there is no immunoassay 
available for the measurement of serum TLI concentrations in ferret (Mustela putorius 
furo) serum [8].   
1.2 Cystic fibrosis  
Cystic fibrosis (CF) is an incurable genetic disease caused by mutations in the CF 
transmembrane conductance regulator (CFTR) gene. Historically, CF was noted to 
primarily affect Caucasians, but CF has now been reported in patients of all ethnicities 
[9]. In the United States, more than 1,000 patients are newly diagnosed every year. Also, 
newborn screening for CF has been responsible for 60 percent of new diagnoses in 2013 
[10]. Infants are screened for CF by an immunoreactive trypsinogen test, which 
measures the concentration of trypsinogen in the blood [4]. Also, a DNA-based test for 
the diagnosis of CF is commercially available and identifies greater than 90% of CFTR 
mutations. This may allow for greater personalized care of CF patients by identifying 
which clinical symptoms are most associated with a particular genotype [11]. The gold 
standard for the diagnosis of CF is an electrolyte test. This test measures chloride 
concentration in sweat after electrical stimulation of a sweat gland. If the chloride 
concentration is greater than 60 mmol/L, the patient is considered CF positive [12].   
There is no cure for CF, but medical advances have increased life expectancy and 
the median age of survival is now greater than 40 years in developed countries [10]. 
Although CF was once thought of as a pediatric disease in which patients do not live into 
adulthood, CF diagnosis and treatment has increased life expectancy drastically in the 
last 50 years. Newborn screening and early diagnosis allow patients to receive the 
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therapy and supplementation they need, before the manifestation of clinical signs. This, 
along with life-long medical treatment, has allowed many patients with CF to live 
relatively normal lives [13]. 
In the 85 years since CF was first described, one of the most important 
discoveries was how the CFTR gene mutation resulted in CF. The CTFR protein 
functions as a chloride and bicarbonate transporter in epithelial and blood cells and 
genetic mutations result in thick mucus, which blocks ducts and secretory cells. Since 
secretory cells are located throughout the body, CF is thought of as a multisystemic 
disease. CF affects upper and lower airways, exocrine pancreas, liver, reproductive tract, 
and gastrointestinal tract [14].   
Lung disease is the most prominent clinical manifestation of CF. First, mucus 
obstructs the airways and submucosal glands. Next, the lungs are colonized with 
pathogenic bacteria because the lungs cannot be properly cleared, which leads to an 
inflammatory response to these bacteria [11]. This chronic respiratory infection may 
become so severe that a lung transplant may be required [15]. In fact, CF accounted for 
15.4% of all adult lung transplants from January 2004 to June 2015 (n = 36,327) [16]. 
Although the lungs are the primary organ affected, the pancreas is one of the 
earliest affected organs [17]. Classic CF presents with sticky mucus and blocked 
pancreatic ducts. This leads to decreased amounts of pancreatic enzymes and zymogens 
being released into the small intestine. Without these enzymes, which are necessary to 
properly digest protein and fat, CF patients are often malnourished and have clinical 
signs of gastrointestinal disease, such as loose stools or diarrhea. The nutritional status of 
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CF patients is highly predictive of survival, and pancreatic enzyme therapy combined 
with a specialized diet can greatly increase longevity [18]. 
1.3 The exocrine pancreas in human patients with cystic fibrosis 
In 1938, Dr. Dorothy Anderson first described necropsy findings in humans with 
cystic fibrosis (CF). She noted the fibrotic cysts formed within the pancreas and named 
the disease cystic fibrosis [19]. In 1989, genetic research of CF determined that a 
defective CFTR gene was responsible for CF [20]. This defective transport protein leads 
to impaired anion (Cl- and HCO3-) transport into the proximal ducts of the pancreas. The 
decreased flow of secretions combined with a high protein concentration can lead to 
precipitation of secreted proteins. These proteins can obstruct intraluminal ducts and 
cause pancreatic destruction [21]. The degree of pancreatic insufficiency and its rate of 
progression are largely linked to genetic factors [17]. There are six classes of CTFR 
mutations, and the mutations can be placed into two groups based on the status of the 
exocrine pancreatic function. Classes I, II, III, and VI are homozygous or compound 
heterozygous for severe alleles and lead to pancreatic insufficiency, while classes IV and 
V are not associated with pancreatic insufficiency [22]. Most CF patients fall into the 
first group, with about 85% of patients requiring pancreatic enzyme supplementation by 
age 2 [13]. Without supplementation, these patients exhibit nutritional deficiencies, 
especially due to the malabsorption of protein, fat, and fat-soluble vitamins in the small 
intestine [23]. Although pancreatitis has been shown to have a low prevalence among CF 
patients, mild CF mutations (classes IV and V) are considered a risk factor for both mild 
acute and chronic pancreatitis [24].  
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1.4 Animal models for cystic fibrosis 
Animal models are an important research tool for studying the mechanisms of 
many diseases. Animal models for cystic fibrosis (CF) were developed not long after the 
genetic mutation of the CFTR was characterized. Several animal models have been 
developed to study CF pathogenesis, including the mouse, rat, zebrafish, pig, and ferret 
[25,26]. Cystic fibrosis is a multisystemic disease that affects several organs and that is 
associated with various clinical signs. The diverse clinical nature of CF has called for a 
diverse set of animal models. Each of these animal models has advantages and 
disadvantages. For example, if CF researchers are interested in studying meconium ileus 
(MI), an intestinal obstruction that occurs in about 15%-20% of newborns with CF, the 
pig would be best used as a model because the CF pig shows a 100% incidence of MI at 
birth. There are also genetically modified CF pigs where CFTR expression has been 
restored in the intestine, which can serve as controls [27]. Development of these animal 
models creates more conduits to better understand CF pathogenesis and create improved 
therapeutic options for humans with CF.  
1.5 Ferret animal model for cystic fibrosis 
At first, most CF research utilizing animal models was done with mouse strains 
with a mutated CFTR gene. However, mouse models lack significant pancreatic and 
pulmonary pathology similar to that of larger mammals [28]. These shortcomings led to 
the development of different CTFR recessive animal models, including rats, pigs, and 
ferrets [27]. CFTR-knockout ferrets exhibit similar disease characteristics to humans, 
especially in the lungs and the exocrine pancreas. Along with a short gestation time and 
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sexual maturation at 4 to 6 months, the similar lung physiology makes the ferret model 
ideal for studying lung infections [29]. Other diseases that have been studied using ferret 
animal models include severe acute respiratory syndrome and influenza virus [30,31]. 
Similar to the lungs, the exocrine pancreas of the ferret is anatomically very similar to 
that of humans. CF ferrets have been shown to exhibit exocrine pancreatic insufficiency 
(EPI), paralleling that observed in human CF patients, where EPI is estimated to develop 
in 80%-90% of CF patients [14].  
1.6 The exocrine pancreas in cystic fibrosis ferrets 
Gastrointestinal disease in CFTR-knockout ferrets has been characterized by 
Xingshen Sun and colleagues [32]. They observed that CF ferrets exhibit progressive 
pancreatic disease after birth. Fecal elastase-1 concentrations and histology were used to 
determine the degree of pancreatic disease. Extensive fibrosis and loss of exocrine 
pancreatic function was observed in 11 of 13 CF ferrets in their study. This parallels 
humans with CF, in which 80%-90% of patients are known to be develop exocrine 
pancreatic insufficiency [33]. Interestingly, the two CF ferrets that had normal pancreatic 
function and histology were raised in the same environment as the other CF ferrets, 
suggesting that genetic factors play an important role in the severity of the disease [32]. 
Using the CF ferret as a model will allow researchers to evaluate genetic and 
environmental factors that determine disease severity as it relates to the exocrine 
pancreas in CF patients.  
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1.7 Acute pancreatitis 
Pancreatitis, an inflammatory disease of the pancreas, is poorly understood and 
can be acute or chronic. In humans, the most common causes of pancreatitis are 
gallstones or alcohol consumption [34]. Chronic pancreatitis can be defined as a 
persistent and progressive inflammatory disease of the pancreas, while acute pancreatitis 
(AP) is a short-lived, inflammatory response of the pancreas that is corrected by an anti-
inflammatory response [35,36]. Smoking and type 2 diabetes may increase the risk for 
acute pancreatitis [37]. In humans, serum amylase and lipase activities above three times 
the upper limit of the upper reference interval are one criterion for a potential diagnosis 
of AP [36]. 
Although the pathophysiology of AP is still not well understood, it is known that 
pancreatic duct obstruction and/or pancreatic cell damage leads to blockage of the 
release of pancreatic enzymes into the small intestine. As the disease progresses, an 
excess of enzymes, such as trypsin, accumulates in acinar cells and leads to acinar cell 
damage. Premature trypsin activation, most likely promoted by cathepsin B, results in 
autodigestion of pancreatic acinar cells [38]. Acinar cell injury then stimulates an 
inflammatory response. The release of cytokines and chemokines attracts inflammatory 
cells, resulting in continued pancreatic destruction. This can lead to necrotic changes in 
the pancreatic tissue and multiple organ dysfunction [39]. Animal models can give 
researchers a better understanding of the pathophysiology of pancreatitis and may lead to 
novel biomarkers and treatments [34]. 
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1.8 Animal models of pancreatitis 
In 1856, the first animal model for pancreatitis was established. This model was a 
rabbit model, where bile and olive oil were injected into the pancreatic duct. To date, 
various rodent models, both non-invasive and invasive, are the most widely used models 
due to their reproducibility and low-cost [34].   
Non-invasive models of pancreatitis include hormone hyperstimulation and 
dietary modification, while invasive models include closing off a duodenal loop or 
ligating the pancreatic duct. For example, the secretagogue caerulein, a cholecystokinin 
(CCK) hormone analogue, stimulates pancreatic enzyme synthesis and secretion, and 
hyperstimulation through administration of caerulein may result in pancreatic cell 
damage. This model is relatively simple and easy to reproduce, while allowing 
investigation of pancreatic cell regeneration after cessation of secretagogue 
administration. Unfortunately, CCK hyperstimulation is not a known cause of AP in 
humans. Similarly, alcohol feeding does not induce AP in many animal models, even 
though it is one of the main causes of AP in humans [38]. There have been many studies 
attempting to combine and modify different strategies for inducing and studying AP in 
animal models to most closely resemble human AP, but every model is lacking in one 
way or another [34]. 
 All animal models of AP lead to clinical signs of lethargy, vomiting, and 
abdominal pain while resulting in mild to severe pancreatitis. Current small animal 
models of pancreatitis include rodents, rabbits, possums, dogs, and cats [40]. As the 
pathophysiology of pancreatitis remains largely unknown, a diverse set of animal models 
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with different methods to induce pancreatitis can help solve different parts of the 
pancreatitis puzzle. Adding the ferret animal model may provide new insights into the 
pathophysiology of human pancreatitis.  
1.9 Potential ferret model of pancreatitis 
As noted previously, the pancreas of the ferret is anatomically and 
physiologically similar to that of humans. Therefore, ferrets may potentially serve as an 
animal model for human pancreatitis. The current mouse and rat pancreatitis models 
usually exhibit mild pancreatitis, and dogs are expensive to house compared to ferrets. 
Many of the procedures that are used to induce pancreatitis in other small mammals 
should be easily reproducible in the ferret [34]. Ferrets currently serve as animal models 
for several other diseases, including cystic fibrosis, severe acute respiratory syndrome 
(SARS), and influenza [32,30,31]. A RIA for the measurement of TLI in ferret serum 
would be an invaluable minimally-invasive tool to facilitate the establishment of a novel 
pancreatitis ferret model. 
 10 
 
2. MATERIALS AND METHODS 
 
2.1 Materials 
Pancreata were collected from euthanized ferrets from various research projects 
by Dr. Engelhardt, Yaling Yi, and colleagues from the University of Iowa Carver 
College of Medicine and were placed into a 15 mL centrifuge tube (two pancreata per 
tube). The tubes were labeled with the identification number of both ferrets and shipped 
overnight on dry ice to the Gastrointestinal Laboratory at Texas A&M University. All 
chemicals used were purchased from Sigma-Aldrich, St. Louis, MO, USA. The 
following materials were also used: 
125Iodine     Perkin Elmer, Waltham, MA, USA 
Bovine serum albumin    Pierce Chemical CO, Rockford, IL, USA  
Coomassie brilliant blue G-250  Pierce Chemical CO, Rockford, IL, USA 
Imperial protein stain    Pierce Chemical CO, Rockford, IL, USA 
Mark 12      Invitrogen, Carlsbad, CA, USA 
NuPAGE 12% Bis-Tris gel    Invitrogen, Carlsbad, CA, USA 
NuPAGE LDS sample buffer   Invitrogen, Carlsbad, CA, USA 
NuPAGE MOPS SDS running buffer  Invitrogen, Carlsbad, CA, USA 
NuPAGE sample reducing agent   Invitrogen, Carlsbad, CA, USA 
Precipitating solution (PPT)   MP Biomedicals, Santa Ana, CA, USA 
Polyacrylamide    Bio-Rad Laboratories, Hercules, CA, USA 
Rabbit carrier solution (RCS)   Sigma Chemicals, St. Louis, MO, USA 
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SeeBlue Plus2     Invitrogen, Carlsbad, CA, USA 
Silver stain kit Pierce     Chemical CO, Rockford, IL, USA 
2.1.1 Instruments and machines 
2470 Automatic Gamma Counter Wizard2® Perkin Elmer, Waltham, MA, USA 
ÄKTA basic & fraction collector Frac-900  GE Healthcare, Uppsala, Sweden 
Benzamidine column    GE Healthcare, Uppsala, Sweden 
Centrifuge 5810R     Eppendorf AG, Hamburg, Germany 
Centrifuge Allegra® X-15R   Beckman Coulter, Brea, CA, USA 
Centrifuge rotor F 34-6-38    Eppendorf AG, Hamburg, Germany 
Centrifuge rotor A-4-81    Eppendorf AG, Hamburg, Germany 
Centrifuge rotor SX4750A AriesTM  Beckman Coulter, Brea, CA, USA 
Gel DocTM XR+ System   Bio-Rad Laboratories, Hercules, CA, USA 
Incubator – Boekel Model 133000  Boekel Scientific, Feasterville, PA, USA 
pH-meter – Orion Star A211    Thermo Scientific, Rockford, IL, USA 
Pipetman® P-20, P-100, P-200, P-1000 Rainin, Woburn, MA, USA  
Pipette E4XLS Multichannel P-300  Rainin, Woburn, MA, USA 
Pipettes E4XLS P-20, P-100, P-300, P-1000  Rainin, Woburn, MA, USA 
Pipette P-5000     Eppendorf Research, Germany 
Polytron homogenizer, PT-MR2100   Kinematica AG, Switzerland 
Power Ease 500 (for electrophoresis)  Invitrogen, Carlsbad, CA, USA 
Sephacryl S-100 26 x 60 HR column  GE Healthcare, Uppsala, Sweden 
Scale - Voyager Pro    Ohaus, Parsippany, NJ, USA 
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Scale - XS6002S    Mettler Toledo, Columbus, OH, USA 
Spectrophotometer - Ultrospec 2000   GE Healthcare, Uppsala, Sweden 
Standard stirrer    VWR, West Chester, PA, USA 
VX-2500 multi-tube vortexer   Fisher Scientific, Pittsburgh, PA, USA 
2.1.2 Disposable materials 
Blue Max™ Jr. (polypropylene, 15 mL) Falcon, Franklin Lakes, NJ, USA 
Centrifuge tubes (polypropylene, 50 mL) VWR, West Chester, PA, USA 
Culture tubes (polypropylene, 12 x 75 mm)  VWR, West Chester, PA, USA 
Culture tubes (polystyrene, 12 x 75 mm)  VWR, West Chester, PA, USA 
Glass culture tubes (12 x 75 mm)   VWR, West Chester, PA, USA 
Parafilm®     VWR, West Chester, PA, USA 
Magnetic micro-stir bar    VWR, West Chester, PA, USA 
Membrane filters 0.2 μM  Pall Corp., Port Washington, NY, USA 
Microcentrifuge tube (1.5 mL)  USA Scientific, Orlando, FL, USA 
Microcentrifuge tube seal-rite (2.0 mL) USA Scientific, Orlando, FL, USA 
Microcentrifuge tube seal-rite (0.5 mL) USA Scientific, Orlando, FL, USA 
Microplates, 96-well ELISA   Greiner Bio-One GmbH, Germany  
Nalgene® syringe filters, polyethersulfone, VWR, West Chester, PA, USA 
25 mm, 0.2 µm 
PD-10 column (SephadexTM G-25M;  GE Healthcare, Uppsala, Sweden 
14.5×50 mm)  
Rainin® pipette tips (10, 250, 1000 μL)  Rainin, Woburn, MA, USA 
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Tips GelWell 0.57 mm 10 μL GT-10-6  Rainin, Woburn, MA, USA 
Weigh paper     VWR, West Chester, PA, USA 
Weigh boats              USA Scientific, Orlando, FL, USA 
2.2 Purification and partial characterization of ferret trypsin from pancreatic tissue 
2.2.1 Sulfuric acid extraction 
Ferret pancreata were received frozen and kept in a -20°C freezer until 
purification. After enough pancreata had been collected, the tissue was removed from 
the freezer and thawed at room temperature. The tissue was then cut up with a scalpel 
blade into 1 cm pieces and any fatty tissue was removed. Extraction of proteins was 
achieved by a standard protocol that was slightly modified to account for the low weight 
of the ferret pancreata. Briefly, 10 mL of .125 M sulfuric acid was added to a beaker 
containing one pancreas, regardless of weight. The beaker was quickly placed into a 
bucket of ice and covered with Parafilm® with one hole in the top. The solution was 
then homogenized with a tissue grinder until the mixture was smooth and all the tissue 
had been liquefied. The mixture was poured into a 50 mL centrifuge tube and spun in the 
centrifuge at 18,000 RCF at 4°C for 45 minutes. The supernatant was carefully decanted 
and saved for further purification while the pellet was set aside for later evaluation. 
2.2.2 Ammonium sulfate precipitation 
Ammonium sulfate precipitation was carried out in two steps. For step one a 0.8 
M ammonium sulfate was used while 3.0 M ammonium sulfate was used for step two. 
The supernatant was kept after the first step, while the pellet was retained after the 
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second step. All fractions were analyzed by SDS-PAGE gel and screened with the 
tryptic activity assay. 
2.2.3 Gel filtration 
Gel filtration was done on a Sephacryl S-100 26 x 60 HR with buffer one (200 
mM NaCl, 50 nM CaCl₂, 0.1 g/L NaN3, pH 2.6). After the column was equilibrated with 
buffer one, the pellets from 3.0 M ammonium sulfate precipitation were completely 
dissolved in 5 mL of the same buffer and then filtered through a 0.2 μM syringe filter. 
The solution was loaded onto the column with a flow rate of 1 mL/min and 5 mL 
fractions were collected for analysis and further purification. 
2.2.4 Assay for tryptic activity 
A 50 μL aliquot was taken from each fraction and the pH was adjusted by the 
addition of 50 μL of buffer two (1 M Tris-HCl, pH 8.0). Fifty μL of a porcine 
enterokinase solution (1 mg/mL in buffer two) was added to activate any trypsinogen 
present. After incubation at 37⁰C, all samples plus controls were assayed for tryptic 
activity using the method described by Schwert and Takenaka [41]. 
2.2.5 Trypsinogen activation 
All fractions that had activity were pooled and the pH was adjusted to 8.0 by 
adding concentrated NaOH. A solution of 15 mL of buffer two and enterokinase was 
added to the concentration of 1 mg/mL to begin activation. Starting off by adding 
approximately 3 mL of the solution it was then left to incubate and the activity was 
checked every two hours. Every two hours, 50 μL was taken from the pool and screened 
for tryptic activity. The time of trypsinogen activation varies widely. If the activity did 
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not increase after 8-10 hours, more of the enterokinase solution was added, and 
screening was continued every two hours. After the activity had plateaued or slightly 
decreased, the solution was then applied onto the benzamidine column. 
2.2.6 Affinity chromatography and inhibition of trypsin 
Affinity chromatography was achieved on a benzamidine sepharose column with 
a series of buffers to wash off contaminants, elute the purified trypsin, and clean up and 
regenerate the column. All fractions were collected and pooled, then the pH was adjusted 
to pH 8.0 using concentrated NaOH. Immediately after pH 8.0 was reached, 2 mL of a 1 
mg/ml Na-p-tosyl-˪-lysine chloro-methyl ketone (TLCK) solution was added to inhibit 
trypsin activity. Once again the activity was monitored, and if such activity persisted, 
more of the TLCK solution was added and the activity was further monitored. The 
trypsin/TLCK solution was left to incubate at room temperature for 6 hours. The 
solution was the dialyzed against 4 L of 1 mM HCl for 4 hours, three times (for a total of 
12 hours). Afterwards, the trypsin was screened for activity to ensure complete 
inhibition.   
2.2.7 Partial characterization 
Pre-cast electrophoresis gels, chamber, power supply, and molecular weight 
markers (SeeBlue Plus2 and Mark 12) were purchased from Invitrogen, Carlsbad, CA, 
USA. Manufacturer’s instructions were followed with the following parameters: 12% 
Bis-Tris gels, 200 V constant voltage for 47 minutes. After electrophoresis, the gels were 
stained with Imperial stain for 45 minutes then destained with H₂O for 2 hours. Finally, 
gel pictures were taken using Gel DocTM XR+ System from Bio-Rad Laboratories, 
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Hercules, CA, USA to determine purity. Finally, the concentration was determined 
before the final prep and storage (Figure 1). The pure ferret trypsin protein was sent to 
the Protein Chemistry Laboratory at Texas A&M University for amino acid sequence 
analysis by Automated Edman Chemistry and to determine sequence homology with 
trypsin of other species. N-terminal amino acid sequence for the first 6 amino acids was 
determined. 
2.3 Production of anti-ferret trypsin antiserum in rabbits 
Two New Zealand White rabbits (Oryctolagus cuniculus) were injected with 
pure ferret trypsin at Lampire Biological Laboratories, Pipersville, Pennsylvania, USA 
for production of anti-ferret trypsin antiserum. Briefly, each rabbit was injected 
subcutaneously with 1 mL of a solution consisting of 300 µg of ferret trypsin in 0.5 mL 
of phosphate buffered saline (PBS) mixed with 0.5 mL complete Freund’s adjuvant. 
Reinoculations with 300 µg of ferret trypsin in 0.5 mL of PBS mixed with 0.5 mL of 
incomplete Freund’s adjuvant were performed 7, 14, 28, 56, and 84 days after initial 
inoculation in order to boost the immune response to the antigen. Blood samples were 
collected by venipuncture of the ear vein after the first injection for the pre-bleed and 
two weeks after each of the last three booster injections for the test bleeds. After a total 
of 6 injections, both rabbits were exsanguinated and the collected serum was sent to the 
Gastrointestinal Laboratory at Texas A&M University for the development of a 
radioimmunoassay (RIA). 
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2.4 Set-up of a RIA for ferret trypsin-like immunoreactivity 
2.4.1 Iodination of ferret trypsin 
Titers of anti-ferret trypsin antibodies in the serum of the rabbits were 
determined using pure ferret trypsin protein radiolabeled with 125I using the chloramine-
T method [42]. All buffers for this procedure were prepared fresh, and the iodination 
procedure was carried out under a fume hood. The bottle containing 125I was kept behind 
a lead shield within the fume hood.  
A miniature stir bar and 10 µL of 0.25 M sodium phosphate buffer (pH 7.5) were 
placed in a 5 mL polystyrene tube above a stir plate. While stirring, 9 µL of 125I (0.1 
mCi/µL at the time of production) was added to the polystyrene reaction tube using a 
Hamilton syringe. Next, 10 µL of purified ferret trypsin in PBS (1 mg/mL) and 10 µL 
chloramine-T solution (2 mg/mL chloramine-T in 0.05 M sodium phosphate buffer) 
were added to the tube. After 45 seconds, 100 µL sodium metabisulfite solution (0.4 
mg/mL Na2S2O5 in 0.05 M sodium phosphate buffer, pH 7.5) and 860 µL potassium 
iodide solution (2 mg/mL KI in 0.05 M sodium phosphate buffer, pH 7.5) were added in 
rapid succession.  
To measure the total radioactivity, two 10 µL aliquots of the 1.0 mL mixture 
were pipetted into separate polystyrene tubes and each diluted with 990 µL of RIA 
buffer (0.05 M sodium phosphate solution, 0.2 g/L NaN3, 5 g/L BSA, pH 7.5). Two 10 
µL aliquots were taken from this 1.0 mL mixture and pipetted into separate 
polypropylene tubes labeled TC for “total count” for measurement in the gamma counter 
(2470 Automatic Gamma Counter Wizard2®).  
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A disposable PD-10 desalting column (SephadexTM G-25M; 14.5×50 mm) was 
equilibrated with 3 column volumes of a concentrated BSA solution (50 mM monobasic 
sodium phosphate solution and 50 mM dibasic sodium phosphate solution, mixed to 
achieve a pH of 7.5, with subsequent addition of 5 g/L BSA and 0.2 g sodium azide) to 
prevent nonspecific protein binding to the dextran resin of the column. The remaining 
980 µL of the original solution was poured onto the column in order to separate the 
iodinated protein from free 125I by size exclusion. The eluent was collected in a 
polystyrene tube as fraction number 1. Subsequently, 1 mL aliquots of RIA buffer were 
used as the mobile phase, and 1 mL fractions of eluent were collected in individual 
polystyrene tubes numbered 2 to 15.  
Ten µL of each eluent fraction was transferred to polypropylene tubes, labeled 1 
through 15. The two 10 µL aliquots labeled TC were used to determine the total 
radioactivity and fractions 1 through 15 were measured in the gamma counter and the 
counts per minute (CPM) were recorded. Using Microsoft Excel to plot the CPM 
measured values versus the fraction number was used to create a curve with two peaks. 
The first peak consisted of fractions 4 and 5, and the second peak consisted of fractions 
10 to 13, corresponding to the fractions with the highest radioactivity. Since the 
iodinated protein has a higher molecular weight than free 125I, it elutes earlier and was 
thus assumed to be contained in fractions 4 and 5.  
This iodination procedure was carried out monthly to ensure high specific 
radioactivity, as 125I has a half-life of 60 days [42]. Fraction 4 had the highest 
radioactivity of all fractions and was chosen for the production of the tracer. Tracer was 
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produced as needed and was adjusted to approximately 30,000 CPM per 100 µL tracer 
by dilution with RIA buffer. Both the final tracer solution and the remainder of fraction 
4 were kept at 4°C and discarded with other radioactive materials after 30 days. 
2.4.2 Ferret trypsin-like immunoreactivity RIA procedure 
Anti-ferret trypsin rabbit antiserum was diluted with RIA buffer to determine the 
best total binding. The following antibody dilutions were assessed to see which dilution 
results in the most specific binding: 1:1000, 1:2000, 1:4000, 1:8000, 1:10,000, and 
1:20,000. Incubation times of 2, 24, and 48 hours after addition of tracer to the sample 
tubes were evaluated. As mentioned previously, the tracer was produced from fraction 4 
of the iodination and was adjusted to approximately 30,000 CPM per 100 μL. Standards 
of pure ferret trypsin were made in concentrations of 0.78, 1.56, 3.13, 6.25, 12.5, 25.0, 
50.0, 100, and 200 μg/L by serial dilution, and standards were kept at -80°C until 
needed.  
Each RIA procedure was carried out in a radiation room at room temperature 
(approximately 23°C). Briefly, each ferret serum sample was diluted 1:10 with RIA 
buffer. Standards were removed from the freezer and 100 µL each were pipetted into 
two polypropylene tubes. Next, 100 µL of diluted ferret serum samples were aliquoted 
into two polypropylene tubes before tracer and antiserum were added to all standards 
and samples.  
The tubes labeled TC contained only 100 μL of tracer. The tubes labeled NB 
contained 200 μL RIA buffer and 100 μL tracer. The tubes labeled B0 contained 100 μL 
of RIA buffer, 100 μL tracer, and 100 μL anti-ferret trypsin antibodies. After 100 μL 
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tracer and 100 μL diluted antiserum were added to all standards and ferret serum 
samples, all tubes were vortexed and allowed to incubate at room temperature for 24 hrs. 
After 24 hours, 100 μL of rabbit carrier serum (1 mL of serum from a healthy rabbit in 
99 mL of RIAB) and 1 mL of precipitating solution were added to every tube, except 
TC. Next, the tubes were vortexed and spun in a centrifuge at 3,800 rpm for 30 minutes 
at 4°C. The polypropylene tubes were promptly removed from the centrifuge and 
transferred to foam racks. Lastly, the samples were decanted and read with the gamma 
counter. 
2.5 Analytical validation of the ferret trypsin-like immunoreactivity RIA 
Excess ferret serum samples from unrelated projects at the Gastrointestinal 
Laboratory at Texas A&M University were used to analytically validate the assay by 
determination of dilutional parallelism, spiking recovery, intra-assay variability, and 
inter-assay variability. Assay sensitivity was assessed by setting up 10 duplicates of B0 
(100 μL anti-ferret trypsin antibodies plus 100 μL RIA buffer) and calculating the mean 
and standard deviation of the raw counts. The mean counts minus three standard 
deviations was calculated and the value estimated on the standard curve. The calculated 
sensitivity was used as the lower limit of detection of the assay. 
All ferret serum samples were kept undiluted at -80°C until use and diluted to the 
standard 1:10 dilution using RIA buffer after thawing the samples at room temperature. 
Assay linearity was evaluated by assessing dilutional parallelism for 7 different serum 
samples at serial dilutions of 1:10, 1:20, 1:40, and 1:80 for each sample. The accuracy of 
the assay was measured by spiking 6 different serum samples with equal volumes of 
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solutions with known concentrations of ferret trypsin (0.39, 0.78, 1.56, 3.12, 6.25, 12.5, 
25, 50 µg/L). The percentage of standard antigen recovery was calculated as the 
observed-to-expected ratio (O/E%):  
O/E% = [observed value (µg/L) / expected value (µg/L)] x 100.  
To evaluate the precision of the RIA, 7 different serum samples were analyzed 10 times 
within the same assay run. The intra-assay coefficient of variation (%CV) was calculated 
as:  
%CV = (standard deviation / mean) x 100.  
Assay reproducibility was evaluated by assaying 9 different serum samples in 10 
separate assay runs, followed by calculating the inter-assay %CVs. All ferret serum 
validation samples were run in duplicate fashion and the same 1:8,000 antiserum dilution 
and a 24 hour incubation time. 
2.6 Ferret trypsin-like immunoreactivity RIA reference interval 
Healthy ferret serum samples from unrelated projects were used for 
establishment of a reference interval. Ferrets were determined to be healthy by owner 
questionnaire. All samples were ran at the standard 1:10 dilution and their concentrations 
recorded. The reference interval for serum ferret TLI was determined based on the 
central 95th percentile measured in 35 healthy ferrets with Microsoft Excel freeware add-
in reference value advisor V2.1, using the robust Box-Cox transformed data [43]. 
2.7 Healthy control ferrets vs. ferrets with acute pancreatitis 
Dr. John Engelhardt and colleagues from the Anatomy and Cell Biology 
Department at the University of Iowa Carver College of Medicine had previously 
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conducted experiments to induce acute pancreatitis (AP) in ferrets. Three ferrets were 
hyperstimulated with caerulein to induce AP and four ferrets were used as healthy 
controls (HC). Control ferrets were kept in the same environment and fed the same diet 
as AP ferrets. Serum obtained from all 7 ferrets used in this study was collected and 
shipped to the Gastrointestinal Laboratory at Texas A&M University and kept at -80°C 
until analysis by the mTLI RIA. Ferret serum not sent to Texas A&M University was 
used to determine serum lipase activities (IU/L) at University of Iowa Carver College of 
Medicine. After analytical validation of the mTLI assay, the 7 ferret serum samples (3 
AP, 4 HC) were analyzed at the standard 1:10 dilution. A Pearson correlation coefficient 
was calculated between the two variables of lipase activity and mTLI concentration 
using GraphPad Prism V7.0 for Windows, GraphPad Software, La Jolla, California 
USA. 
 23 
 
3. RESULTS 
 
3.1 Purification and partial characterization of ferret trypsin 
Trypsin was successfully purified from ferret pancreatic tissue. After adding 10 
mL of 0.125 M sulfuric acid to one minced ferret pancreas and after homogenizing the 
solution with a tissue grinder, the solution was centrifuged. This procedure yielded about 
9.5 mL of supernatant that was kept for further purification. A two-step ammonium 
sulfate precipitation with increasing concentrations of ammonium sulfate produced two 
solutions with a pellet and a supernatant. The supernatant was kept after the first 
precipitation, while the pellet was kept after the second precipitation step. The pellet 
from the ammonium precipitation was loaded onto a gel filtration column, resulting in a 
peak after approximately 50-60 mL of buffer was applied. The fractions that contained 
the peak were saved for tryptic activity screening and SDS-PAGE analysis. Tryptic 
activity between purification steps was measured as described previously by Schwert 
and Takenaka [41]. After pooling all fractions with tryptic activity and adjusting the pH 
to 8.0, trypsinogen was activated by addition of an enterokinase solution. After activity 
reached a maximum plateau, the solution was applied to a benzamidine column. Affinity 
chromatography with a benzamidine column led to a single peak (Figure 1) that 
contained purified trypsin eluting after addition of elution buffer (50 mM Sodium 
acetate, 2 mM CaCl2, pH 3.25). After adjusting the pH to 8.0, 2 mL of a 1 mg/ml Na-p-
tosyl-˪-lysine chloro-methyl ketone (TLCK) solution was added to inhibit trypsin 
activity for storage at -20°C. 
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 Figure 1. Affinity chromatography of partially purified ferret trypsin. This figures shows a representative chromatogram of affinity chromatography on a benzamidine 
column. The dark blue line shows the absorbance at a wavelength of 280 nm during chromatography. The green numbers represent the fractions. The pink dotted lines 
indicate injection of protein onto the column. The light blue line shows the concentration (%) of elution buffer. The peak indicated by the arrow represents pure ferret 
trypsin. 
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The molecular weight of ferret trypsin was estimated by SDS-PAGE stained with 
Coomassie blue stain to be between 22-25 kDa (Figure 2). The amino acid sequence of 
the first six amino acids of the mature end of the trypsin was determined to be: I-V-G-G-
X-T (X is an unknown amino acid). The amino acid sequence was determined to be 
highly homologous to trypsin from several other species (Figure 3) according to the 
sequence analysis report provided by the Protein Chemistry Laboratory at Texas A&M 
University. 
 
 
 
 
 
Figure 2. SDS-PAGE gel analysis of fractions after affinity chromatography. Lanes 1 and 9 are molecular weight markers with 
weights (kDa) in red. Lane 2 is an aliquot of partially purified ferret trypsin before affinity chromatography. Lanes 3 through 8 
are the five fractions with tryptic activity taken from affinity chromatography. The single band in lanes 3, 4, 5, 7, and 8 
represent pure ferret trypsin. 
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3.2 Production of anti-ferret trypsin antiserum in rabbits 
 Serum anti-ferret trypsin antibody titers were evaluated in both rabbits after 
inoculation. After the last inoculation, the antibody titers at different dilutions were 
determined by RIA (Figures 4a & 4b). Titers from both rabbits were sufficient for RIA 
development.   
 
 
 
 
 
 
 
 
Figure 3. Sequence homology. This figure shows the N-terminal amino acid sequence of trypsinogen from 
different mammalian species using the one letter amino acid code: human trypsinogen 1 and 3, anionic and 
cationic porcine trypsinogen, rat trypsinogen 1 and 2, feline trypsinogen, canine anionic trypsinogen, and ferret 
trypsin-like protein [44,45,46,47,48]. 
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Figure 4. Rabbit antibody titers. This figure shows serum anti-ferret trypsin antibody titers of rabbit 1 (a) and 2 (b). Both lines 
represent the serum collected after the final inoculation. The figure displays % binding, as determined by RIA, at different 
dilutions (from 1:500 to 1:256,000). 
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3.3 Development and analytical validation of a RIA for ferret trypsin-like 
immunoreactivity 
 Monthly iodination procedures were carried out to ensure quality binding, as 125I 
is known to have a half-life of 60 days [42]. Fraction 4 from the iodination procedure 
was used for the production of tracer and adjusted to 30,000 CPM per 100 μL for each 
radioimmunoassay (RIA). Every RIA experiment used the same 1:8,000 antibody 
dilution from rabbit 1 and 24 hour incubation after addition of tracer. 
 A representative standard curve for the ferret trypsin-like immunoreactivity RIA 
is shown in Figure 5. Observed-to-expected ratios for dilutional parallelism for the 7 
serum samples tested ranged from 95.2% to 119.4% (mean ± standard deviation [s], 
105.7% ± 8.5%) (Table 1). Observed-to-expected ratios for spiking recovery for the 6 
serum samples assayed ranged from 94.5% to 113.0% (mean ± [s], 103.9% ± 7.2%) 
(Table 2). Coefficients of variation for intra-assay variability for the 7 serum samples 
analyzed were 4.1%, 3.5%, 5.3%, 5.7%, 4.3%, 3.5%, and 2.7% (Table 3). Also, 
coefficients of variation for inter-assay variability for the 9 serum samples tested were 
7.3%, 6.4%, 4.2%, 3.5%, 5.2%, 5.4%, 5.1%, 7.5%, and 8.2% (Table 4). The sensitivity 
of the assay was calculated to be 0.55 μg/L. The healthy reference interval (n = 35) was 
determined to be 17.7 to 123.2 μg/L. 
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Figure 5. mTLI RIA standard curve. This figure shows one representative standard curve for the mTLI RIA. Standards are marked with red plus signs. 
Concentrations of standards are marked on the x-axis in logarithmic form. %B/B0 values are on the y-axis and are calculated using a normalized four 
parameter fit equation. 
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Table 1. This table shows the serial dilution of 7 serum samples throughout the working range. Observed-to-expected ratios are in bold and the 
minimum, maximum, mean, and standard deviation of those 7 observed-to-expected ratios is provided in the box. 
Dilution
Observed 
(μg/L)
Expected 
(μg/L)
O/E(%) Dilution
Observed 
(μg/L)
Expected 
(μg/L)
O/E(%)
1:10 153.5 1:10 8.0
1:20 90.3 76.8 117.7 1:20 4.0 4.0 101.1
1:40 46.5 38.4 121.2 1:40 2.0 2.0 100.4
1:80 27.8 19.2 144.9 1:80 0.6 1.0 61.8
119.4 100.8
Dilution
Observed 
(μg/L)
Expected 
(μg/L)
O/E(%) Dilution
Observed 
(μg/L)
Expected 
(μg/L)
O/E(%)
1:10 128.6 1:10 7.0
1:20 64.9 64.3 100.9 1:20 3.6 3.5 104.7
1:40 33.3 32.2 103.6 1:40 1.7 1.7 98.6
1:80 20.1 16.1 125.0 1:80 1.0 0.9 111.2
102.3 101.7
Dilution
Observed 
(μg/L)
Expected 
(μg/L)
O/E(%) Dilution
Observed 
(μg/L)
Expected 
(μg/L)
O/E(%)
1:10 76.9 1:10 3.5
1:20 39.6 38.5 103.0 1:20 2.0 1.8 117.0
1:40 16.8 19.2 87.4 1:40 1.0 0.9 112.2
1:80 7.7 9.6 80.1 1:80 0.5 0.4 121.2
95.2 114.6
Dilution
Observed 
(μg/L)
Expected 
(μg/L)
O/E(%)
1:10 13.9 Min 95.2
1:20 7.2 7.0 103.4 Max 119.4
1:40 3.8 3.5 108.7 Mean 105.7
1:80 1.8 1.7 104.1 SD 8.5
106.0
Table 1. Dilutional parallelism of 7 ferret serum samples
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Table 2. This table shows data from spiking recovery of 6 serum samples in the lower and middle regions of the working range. Observed-to-
expected ratios are in bold and the minimum, maximum, mean, and standard deviation of those 6 observed-to-expected ratios is provided in the 
box. 
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3.4 Healthy control ferrets vs. ferrets with acute pancreatitis 
Serum total lipase activity in ferret serum was analyzed at the University of Iowa 
Carver College of Medicine. The serum total lipase activities for control ferrets were 
112.5, 75.9, 119.2, and 86.0 IU/L while AP ferrets had activities of 144.6, 276.9, and 
334.2 IU/L. In the serum from the same ferrets sent to the Gastrointestinal Laboratory, 
the four control ferrets had trypsin-like immunoreactivity (mTLI) RIA concentrations of 
23.0, 24.0, 24.5, and 25.3 μg/L, and the three ferrets with experimentally induced acute 
pancreatitis had mTLI concentrations of 62.8, 76.2, and 143.6 μg/L. These two 
biomarkers correlated well (Pearson r = 0.70), as shown in Figure 6. 
 
 
 
Table 3. This table shows the results of intra-assay variability of the mTLI RIA for 7 different serum samples, from highest to lowest concentration. 
Coefficients of variation (%CV) are shown in bold. 
Table 4. This table shows the results of inter-assay variability of the mTLI RIA for 9 different serum samples, from highest to lowest concentration. 
Coefficients of variation (%CV) are shown in bold. 
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Figure 6. Healthy controls vs. acute pancreatitis ferrets. Correlation between serum total lipase activity (IU/L) and serum mTLI concentration 
(μg/L) for healthy control ferrets (black dots) and ferrets with acute pancreatitis (red dots). The calculated Pearson correlation coefficient, r, 
was 0.70. All acute pancreatitis ferrets had higher total serum total lipase activities and mTLI concentrations than healthy controls. 
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4. DISCUSSION 
 
4.1 Purification and partial characterization of ferret trypsin 
 This is the first report of the purification of ferret trypsin from pancreatic tissue. 
The purification procedure followed modified versions of trypsin purification procedures 
reported for other species [47,49]. The assay for tryptic activity was performed along 
with SDS-PAGE analysis to determine which aliquots should be used for the next steps 
of purification.   
 Sulfuric acid extraction and ammonium sulfate precipitation are widely used 
purification methods [50]. Gel filtration chromatography is a traditional separation 
technique where larger molecules elute before smaller molecules, separating proteins by 
molecular size [51]. Affinity chromatography is another widely used method for protein 
purification. In general, a ligand molecule binds to the molecule of interest and is 
immobilized. Contaminating molecules are eluted by washing the column with different 
buffers with different properties (pH, NaCl concentration, etc.) until the molecule of 
interest is ready to be eluted [52,53].  
After the final affinity chromatography purification step, the purified material 
showed a single band on SDS-PAGE when stained with Coomassie blue stain (Figure 2).  
The molecular weight of ferret trypsin was estimated to between 22-25 kDa, similar to 
trypsins and trypsinogens from other species. For example, canine cationic trypsin is 
reported to have a molecular mass of 23.8 kDa and feline trypsinogen and feline trypsin 
are reported to have a molecular mass of 22.6 kDa and 21.0 kDa, respectively [48,47]. 
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The N-terminal amino acid sequence of ferret trypsin was homologous to that of trypsin 
in other species (Figure 3). Ferret trypsin may have a modified amino acid in position 5 
that cannot be identified by the standard procedures of Edman degradation.   
4.2 Production of anti-ferret trypsin antiserum in rabbits 
 Pure ferret trypsin was sent to Lampire Biological Laboratories, Pipersville, 
Pennsylvania, USA for production of anti-ferret trypsin antiserum in rabbits. The 
vaccination protocol was slightly modified from their standard antibody production 
protocol, adding another inoculation to ensure high antibody titers. Both rabbits had an 
adequate immune response (Figures 4a & 4b). In conclusion, anti-ferret trypsin 
antiserum was successfully raised in two New Zealand White rabbits. Aliquots from 
both rabbits were used in the development of the mTLI RIA. 
4.3 Development and analytical validation of a RIA for ferret trypsin-like 
immunoreactivity 
 A radioimmunoassay (RIA) for the measurement of ferret trypsin-like 
immunoreactivity (mTLI) in serum was successfully established. There are no 
standardized cut-off values for observed-to-expected ratios for dilutional parallelism or 
spiking recovery nor for coefficients of variation for intra-assay and inter-assay 
variability. In our laboratory, acceptable observed-to-expected ratios are considered to 
range from 80% to 120%, and acceptable coefficients of variation are under 10% to 
15%. Observed-to-expected ratios for serial dilution were between 95.2% and 119.4%, 
which suggests the assay is sufficiently linear (Table 1). Observed-to-expected ratios for 
spiking recovery ranged from 94.5 to 113.0%, which suggests the assay is accurate 
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(Table 2). Coefficients of variation for intra-assay variability were all less than 6.0%, 
which suggest that the assay is sufficiently precise (Table 3). Also, coefficients of 
variation for inter-assay variability were all less than 9.0%, which suggests that the assay 
is reproducible (Table 4).  
The reference interval for mTLI (n = 35) was determined to be 17.7 to 123.2 
μg/L. This assay has a working range of 0.55 to 200 μg/L, as defined by the lower limit 
of detection and the highest standard concentration, and the healthy reference interval is 
well within that range.  
In summary, the mTLI RIA described here was sufficiently sensitive, linear, 
accurate, and reproducible for use.  
4.4 Healthy control ferrets vs. ferrets with acute pancreatitis 
Samples from a small study at University of Iowa Carver College of Medicine 
consisted of three ferrets induced to have acute pancreatitis and four healthy control 
ferrets were used to demonstrate the biological relevance of the mTLI RIA described. 
Serum total lipase activity in ferret serum was measured at the University of Iowa 
Carver College of Medicine. Serum total lipase activity and mTLI concentrations 
correlated well, with a calculated Pearson correlation coefficient, r, of 0.70 (Figure 6). 
However, no other statistical analysis was performed as the small sample size provided 
little statistical power. Further assessment of mTLI in ferrets with AP and CF is 
therefore needed. 
 
 
 37 
 
4.5 Limitations 
Although the major goal of developing and analytically validating a 
radioimmunoassay for the measurement of trypsin-like immunoreactivity in ferret serum 
was accomplished, the study was not without limitations. During the purification, the 
methods used were carried out with cost-effectiveness in mind. Only the first 6 amino 
acids of the N-terminal end were determined to save cost. However, the sequence 
identified is homologous to trypsin from other species [44,45,46,47,48] so the author is 
confident that the protein purified was ferret trypsin/trypsinogen.  
Another limitation was the ferret serum samples used for RIA validation and 
construction of a reference interval in this study had been collected for unrelated projects 
conducted at the Gastrointestinal Laboratory at Texas A&M University between 2008 
and 2010. At that time, ferret serum samples were collected and logged, accompanied by 
owner questionnaires that categorized the ferret as either healthy or diseased. Serum 
samples had remained frozen at -80°C since 2010. Therefore, degradation of serum 
sample quality could have affected our results, potentially resulting in a falsely lowered 
reference interval.  
The sample size of healthy ferret samples (n = 35) may be considered small, and 
these ferrets were only determined healthy based on owner questionnaires. However, this 
may be overcome with studies that provide their own healthy controls, allowing direct 
comparison of healthy and diseased groups. For example, the three acute pancreatitis 
ferret serum samples had mTLI concentrations that were at least twice as high as those 
of the four healthy controls from the same experiment. 
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The ferret serum samples provided by the University of Iowa Carver College of 
Medicine demonstrated that the mTLI concentrations of AP ferrets are higher than those 
of healthy ferrets. However, another limitation was the small sample size providing 
limited statistical power when comparing the two groups. Future studies of ferrets with 
induced pancreatitis are being conducted, and plans have been made to have serum 
harvested and sent to the Gastrointestinal Laboratory at Texas A&M University for 
mTLI analysis. 
Lastly, although ferrets serve as an established animal model for CF [30], we did 
not assay any serum samples from CF ferrets. We would expect serum mTLI 
concentrations of adult CF ferrets to be much lower than those of healthy controls, due 
to pancreatic acinar cell destruction. A logical next step would be to measure serum 
mTLI from CFTR-knockout ferrets and healthy control ferrets. 
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5. CONCLUSIONS 
 
  The major objective of this project, to develop and analytically validate a 
radioimmunoassay for the measurement of ferret trypsin-like immunoreactivity (mTLI), 
was successfully accomplished. In order to develop the mTLI radioimmunoassay (RIA), 
ferret trypsin had to be purified and antiserum against this protein was raised in rabbits. 
Then the RIA was developed and analytically validated, a reference interval for healthy 
ferrets was established, and a small study with four clinically healthy ferrets and three 
ferrets with induced acute pancreatitis (AP) was conducted. 
Ferret trypsin was purified from pancreatic tissue using slightly modified 
protocols described previously [47,49,52,53]. Partial characterization consisted of SDS-
PAGE analysis of ferret trypsin that estimated the molecular mass to be between 22-25 
kDa, and the N-terminal amino acid sequence of the first 6 amino acids was homologous 
to sequences reported for trypsins from other species (Figure 3) [44,45,46,47,48]. After 
purification, the first step toward immunoassay development was the production of 
antiserum directed against ferret trypsin raised in New Zealand White rabbits by 
repeated inoculations of solutions containing a mixture of ferret trypsin and complete or 
incomplete Freund’s adjuvant. Antiserum titers from both rabbits were used in the 
establishment of the mTLI RIA. 
We developed and analytically validated an in-house RIA for the measurement of 
mTLI that is analytically sensitive, accurate, precise, reproducible, and sufficiently linear 
for the measurement of TLI in serum samples from ferrets. The working range of the 
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assay was 0.55 to 200 μg/L. A reference interval for the mTLI RIA was established, 
although the sample size may be considered small (n = 35).  
A small pilot study conducted at the University of Iowa Carver College of 
Medicine evaluated serum mTLI concentrations in three ferrets with induced pancreatitis 
and four healthy control ferrets. Serum lipase activities were measured by Dr. 
Engelhardt and colleagues at the University of Iowa Carver College of Medicine and 
those results were sent along with leftover ferret serum for analysis of serum mTLI RIA 
concentrations. We demonstrated that the mTLI concentrations of AP ferrets are higher 
than the mTLI concentrations of healthy ferrets in this small pilot study. These findings 
correlated with those for serum lipase activity with a Spearman r = 0.70 (Figure 6). 
Correlation between these two assays suggests that mTLI concentration may be a useful 
marker for exocrine pancreatic function during AP. 
In conclusion, further studies are needed to determine if the mTLI RIA is useful 
in evaluating both spontaneous and experimental exocrine pancreatic disorders in ferrets. 
CF and pancreatitis are two conditions for which researchers have the option for using 
several different animal models, and each animal model has its strengths and 
weaknesses. This will allow researchers to use their similarities and differences to better 
understand life-threatening diseases and to develop life-saving modalities. Both models 
may benefit using a minimally invasive marker, such as mTLI, to assess exocrine 
pancreatic function. 
 
 41 
 
REFERENCES 
 
1. Travis J, Roberts RC. Human trypsin. Isolation and physical-chemical 
characterization. Biochemistry 1969;8:2884-2889. 
2. Geokas MC, Largman C, Brodrick JW, Johnson JH. Determination of human 
pancreatic cationic trypsinogen in serum by radioimmunoassay. American 
Journal of Physiology: Gastrointestinal & Liver Physiology 1979;236:E77. 
3. Steiner JM, Williams DA. Serum feline trypsin-like immunoreactivity in cats 
with exocrine pancreatic insufficiency. Journal of Veterinary Internal Medicine 
2000;14:627-629. 
4. Sarles J, Giorgi R, Berthézène P, Munck A, Cheillan D, et al. Neonatal screening 
for cystic fibrosis: comparing the performances of IRT/DNA and IRT/PAP. 
Journal of Cystic Fibrosis 2014;13:384-390. 
5. Williams DA, Batt RM. Sensitivity and specificity of radioimmunoassay of 
serum trypsin-like immunoreactivity for the diagnosis of canine exocrine 
pancreatic insufficiency. Journal of the American Veterinary Medical 
Association 1988;192:195-201. 
6. Steiner JM, Medinger TL, Williams DA. Development and validation of a 
radioimmunoassay for feline trypsin-like immunoreactivity. American Journal of 
Veterinary Research 1996;57:1417-1420. 
7. Grulke, S. Equine trypsin: purification and development of a radio-immunoassay. 
Veterinary Research 2003;34:317-330. 
 42 
 
8. Yan Z, Stewart ZA, Sinn PL, Olsen JC, Hu J, McCray PB, Engelhardt JF. Ferret 
and pig models of cystic fibrosis: prospects and promise for gene therapy. 
Human Gene Therapy Clinical Development 2014;26:38-49.  
9. Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical 
application. Nature Reviews Genetics 2015;16:45-56. 
10. Elborn JS. Cystic fibrosis. The Lancet 2016: DOI: 
http://dx.doi.org/10.1016/S0140-6736(16)00576-6. 
11. Montgomery GS, Howenstine M. Cystic fibrosis. Pediatric Review 2009;30:302-
309. 
12. O'Sullivan BP, Freedman SD. Cystic fibrosis. The Lancet 2009;373:1891-1904. 
13. Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H. Evidence-
based practice recommendations for nutrition-related management of children 
and adults with cystic fibrosis and pancreatic insufficiency: results of a 
systematic review. Journal of the American Dietetic Association 2008;108:832-
839. 
14. Gibson-Corley KN, Meyerholz DK, Engelhardt JF. Pancreatic pathophysiology 
in cystic fibrosis. The Journal of Pathology 2016;238:311-320. 
15. Morrell MR, Pilewski JM. Lung transplantation for cystic fibrosis. Clinics in 
Chest Medicine 2016;37:127-138. 
16. Yusen RD, Edwards LB, Dipchand AI, Goldfarb SB, Kucheryavaya AY, et al. 
Registry of the International Society for Heart and Lung Transplantation: thirty-
third adult lung and heart-lung transplant report; focus theme: primary diagnostic 
 43 
 
indications for transplant. The Journal of Heart and Lung Transplantation 
2016;35:1158-1169. 
17. Wilschanski M, Novak I. The cystic fibrosis of exocrine pancreas. Cold Spring 
Harbor Perspectives in Medicine 2013;3:1-17. 
18. Murphy AJ, Buntain HM, Wainwright CE, Davies PS. The nutritional status of 
children with cystic fibrosis. British Journal Nutrition 2006;95:321-324. 
19. Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease: a 
clinical and pathologic study. American Journal of Diseases of Children 
1938;56:344-399. 
20. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, et al. 
Identification of the cystic fibrosis gene: genetic analysis. Science 
1989;245:1073-1080. 
21. Wilschanski M, Durie PR. Patterns of GI disease in adulthood associated with 
mutations in the CFTR gene. Gut 2007;56:1153-1163. 
22. Wang Y, Wrennall JA, Cai Z, Li H, Sheppard DN. Understanding how cystic 
fibrosis mutations disrupt CFTR function: from single molecules to animal 
models. International Journal of Biochemistry and Cell Biology 2014;52:47-57. 
23. Sabharwal S. Gastrointestinal manifestations of cystic fibrosis. Journal of 
Gastroenterology and Hepatology 2016;12:43-47. 
24. Durno C, Corey M, Zielenski J, Tullis E, Tsui LC, Durie P. Genotype and 
phenotype correlations in patients with cystic fibrosis and pancreatitis. 
Gastroenterology 2002;123:1857-1864. 
 44 
 
25. Olivier AK, Gibson-Corley KN, Meyerholz DK. Animal models of 
gastrointestinal and liver diseases. Animal models of cystic fibrosis: 
gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology. 
American Journal of Physiology - Gastrointestinal and Liver Physiology 
2015;308:G459-G471. 
26. Navis A, Bagnat M. Loss of CFTR function leads to pancreatic destruction in 
larval zebrafish. Developmental Biology 2015;399:237-248. 
27. Stoltz DA, Rokhlina T, Ernst SE, Pezzulo AA, Ostedgaard LS, et al. Intestinal 
CFTR expression alleviates meconium ileus in cystic fibrosis pigs. Journal of 
Clinical Investigation 2013;123:2685-2693. 
28. Scholte BJ, Davidson DJ, Wilke M, de Jonge HR. Animal models of cystic 
fibrosis. Journal of Cystic Fibrosis 2004;3:183-190. 
29. Lavelle GM, White MM, Browne N, McElvaney NG, Reeves EP. Animal 
models of cystic fibrosis pathology: phenotypic parallels and divergences. 
BioMed Research International 2016;2016:1-14. 
30. Chu YK, Ali GD, Jia F, Li Q, Kelvin D, et al. The SARS-CoV ferret model in an 
infection-challenge study. Virology 2008;374:151-163. 
31. Belser JA, Katz JM, Tumpey TM. The ferret as a model organism to study 
influenza A virus infection. Disease Models & Mechanisms 2011;4:575-579. 
32. Sun X, Olivier AK, Yi Y, Pope CE, Hayden HS, et al. Gastrointestinal pathology 
in juvenile and adult CFTR-knockout ferrets. The American Journal of Pathology 
2014;184:1309-1322. 
 45 
 
33. Baker SS, Borowitz D, Duffy L, Fitzpatrick L, Gyamfi J, Baker RD. Pancreatic 
enzyme therapy and clinical outcomes in patients with cystic fibrosis. Journal of 
Pediatrics 2005;146:189-193. 
34. Hue Su K, Cuthbertson C, Christophi C. Review of experimental animal models 
of acute pancreatitis. HPB: Official Journal of the International Hepato Pancreato 
Biliary Association 2006;8:264-286. 
35. Majumder S, Chari ST. Chronic pancreatitis. The Lancet 2016;387:1957-1966. 
36. Granger J, Remick D. Acute pancreatitis: models, markers, and mediators. Shock 
2005;24:45-51. 
37. Lankisch PG, Apte M, Banks PA. Acute pancreatitis. The Lancet 2015;386:85-
96. 
38. Pandol SJ, Saluja AK, Imrie CW, Banks PA. Acute pancreatitis: bench to the 
bedside. Gastroenterology 2007;132:1127-1151. 
39. Ruben DS, Scorpio DG, Gabrielson KL, Simon BW, Buscaglia JM. Refinement 
of canine pancreatitis model: inducing pancreatitis by using endoscopic 
retrograde cholangiopancreatography. Comparative Medicine 2009;59:78-82. 
40. Hunter WM, Greenwood FC. Preparation of iodine-131 labelled human growth 
hormone of high specific activity. Nature 1962;194:495-496. 
41. Schwert GW, Takenaka Y. A spectrophotometric determination of trypsin and 
chymotrypsin. Biochimica et Biophysica Acta 1955;16:570-575. 
42. Bailey GS. The chloramine T method for radiolabeling protein. The Protein 
Protocols Handbook. Walker JM. Totowa, NJ, Humana Press: 2002;963-965. 
 46 
 
43. Geffre A, Concordet D, Braun JP, Trumel C. Reference Value Advisor: a new 
freeware set of macroinstructions to calculate reference intervals with Microsoft 
Excel. Veterinary Clinical Pathology 2011;40:107-112. 
44. Figarella C, Negri GA, Guy O. The two human trypsinogens. Inhibition spectra 
of the two human trypsins derived from their purified zymogens. European 
Journal of Biochemistry 1975;53:457-463. 
45. Louvard MN. On bovine and porcine anionic trypsinogens. Biochimica et 
biophysica acta 1974;371:177-185. 
46. MacDonald RJ. Two similar but non-allelic rat pancreatic trypsinogens. 
Nucleotide sequences of the cloned cDNAs. Journal of Biological Chemistry 
1982;257:9724-9732. 
47. Steiner JM, Medinger TL, Williams DA. Purification and partial characterization 
of feline trypsin. Comparative Biochemistry and Physiology - Part B: 
Biochemistry & Molecular Biology 1997;116:87-93. 
48. Pinsky SD. Differential regulation of trypsinogen mRNA translation: full-length 
mRNA sequences encoding two oppositely charged trypsinogen isoenzymes in 
the dog pancreas. Molecular and Cellular Biology 1985;5:2669-2676. 
49. Williams DA, Batt RM, Beynon RJ. A simple procedure for the purification of 
the zymogens and active forms of canine anionic trypsin, cationic trypsin and 
chymotrypsin. Biochemical Society Transactions 1983;11:351-351. 
50. Wood WI. Tables for the preparation of ammonium sulfate solutions. Analytical 
Biochemistry 1976;73:250-257. 
 47 
 
51. Laurent TC. A theory of gel filtration and its experimental verification. Journal 
of Chromatography 1964;14:317-330. 
52. Hixson HF. Affinity chromatography of bovine trypsin and thrombin. Methods in 
Enzymology 1974;34:440-448. 
53. Temler RS, Kagi JH. Isolation of human trypsin by affinity chromatography. 
Enzyme 1977;22:249-255. 
 
